RALPH BARIC CRIMINAL EVIDENTIARY DOSSIER

PROSECUTENOW.IO

SARS-CoV Patent – Baric UNC Chapel Hill

Methods for producing recombinant coronavirus

Patent	US-7279327-B2
Inventor	CURTIS KRISTOPHER M (US) YOUNT BOYD (US) BARIC RALPH S (US)
Assignee	UNIV NORTH CAROLINA (US)
Dates	Grant 2007/10/09 Priority 2001/04/20

This web page summarizes information in PubChem about patent US-7279327-B2. This includes chemicals mentioned, as reported by PubChem contributors, as well as other content, such as title, abstract, and International Patent Classification (IPC) codes. To read more about how this page was constructed, please visit the PubChem patents help page.

PubChem

1 Abstract

A helper cell for producing an infectious, replication defective, coronavirus (or more generally nidovirus) particle cell comprises (a) a nidovirus permissive cell; (b) a nidovirus replicon RNA comprising the nidovirus packaging signal and a heterologous RNA sequence, wherein the replicon RNA further lacks a sequence encoding at least one nidovirus structural protein; and (c) at least one separate helper RNA encoding the at least one structural protein absent from the replicon RNA, the helper RNA(s) lacking the nidovirus

- See Methods for producing recombinant coronavirus - Patent US-7279327-B2 - PubChem (nih.gov)

SARS-COV PATENT HISTORY

May 21, 2000 – Baric seeks patent on coronavirus family for their commercial benefit.

April 4, 2001 - Baric seeks to patent a means of producing “an infectious, replication defective, coronavirus.”

October 9, 2007 - Baric granted patent 7,279,327-B2 for a method of producing recombinant coronavirus.

Funded by NIH - grant AI23946-08

NIH FUNDED BARIC'S RESEARCH

- Design, development, and weaponization of Coronavirus
- Design, development, and weaponization of Spike protein
- Design and development of Remdesivir

R01 AI	Baric, Ralph S. / University of North Carolina Chapel Hill	
NIH 2004 R01 AI	Studies into the Mechanisms for MHV Replication Baric, Ralph S. / University of North Carolina Chapel Hill	$345,202
NIH 2004 R01 GM	Reverse Genetics with A Coronavirus Infectious Construct Baric, Ralph S. / University of North Carolina Chapel Hill	$253,321
NIH 2003 R01 AI	Studies into the Mechanisms for MHV Replication Baric, Ralph S. / University of North Carolina Chapel Hill	$519,733
NIH 2003 R01 GM	Reverse Genetics with A Coronavirus Infectious Construct Baric, Ralph S. / University of North Carolina Chapel Hill	$253,321
NIH 2003 R01 AI	Susceptibility and Protective Immunity to Noroviruses Baric, Ralph S. / University of North Carolina Chapel Hill	$129,665
NIH 2002 R01 GM	Reverse Genetics with A Coronavirus Infectious Construct Baric, Ralph S. / University of North Carolina Chapel Hill	$253,321
NIH 2001 R01 GM	Reverse Genetics with A Coronavirus Infectious Construct Baric, Ralph S. / University of North Carolina Chapel Hill	$247,772
NIH 2001 R01 AI	Studies Into the Mechanisms for Mhv Replication Baric, Ralph S. / University of North Carolina Chapel Hill	$207,269

- See https://grantome.com/search?q=@author%20%20Ralph%20Baric

Fauci - NIH Funding of Baric's Research

- 161+ NIH funded research Studies 1997 - 2021
- Over $44M in funding
- Direct support and cooperation by Fauci
  - Coronavirus development
  - Spike protein bio-weapon
  - Remdesivir development and deployment



- See https://grantome.com/search?q=@author%20%20Ralph%20Baric

REMDESIVIR FUNDING

- Creation and pre-clinical research
  - Patented August 2016
  - University of North Carolina at Chapel Hill
  - Gilead Sciences
- Funding sources
  - Centers for Disease Control and Prevention (CDC),
  - Department of Defense (DOD), and
  - National Institutes of Health (NIH)

- UNITED STATES ACCOUNTABility office report to congressional addressees, March 2021

Contracts for preclinical research service			
Preclinical research service contract PC18VB9936 Evaluation of Remdesivir in Hamster Model of Yellow Fever Virus	2018	$18,000	Utah State University
Preclinical research service contract PC20VB13256 Efficacy of Remdesivir in Hamster Model of Yellow Fever Virus	2019	$27,000	Utah State University
Preclinical research service contract IV20RDB13570 Evaluation of Remdesivir for In Vitro Antiviral Activity against SARS-CoV-2	2020	$1,008	Utah State University
Cooperative agreements			
Cooperative agreement U19AI109680 Antiviral Drug Discovery and Development Center – Coronavirus	2014-2020	$2,500,000	University of Alabama at Birmingham[a]
Cooperative agreement U19AI142759 Antiviral Drug Discovery and Development Center – Coronavirus	2019-2023	$400,000	University of Alabama at Birmingham[a]
Cooperative agreement UM1AI068632 Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the U.S.	2020	$942,554	Johns Hopkins University
Grants			
Grant F31AI133952 Coronavirus Antiviral Nucleoside Analogs: Inhibition and Reduced Susceptibility	2017-2019	$25,140	Vanderbilt University
Grant R01AI132178 Broad-Spectrum Antiviral GS-5734 to Treat MERS-CoV and Related Emerging CoV	2017-2021	$5,863,765	University of North Carolina at Chapel Hill
Grant R21AI147057 Mechanistic Understanding and Inhibition of Zika NS5 Protein	2020	$155,000	University of California at Riverside
Grant R00AI123498 Structural Studies of the Corona Virus Life Cycle	2020-2021	$129,120	University of Wisconsin-Madison
Grant R01AI150246 Small Molecule Screening to Identify Novel SARS-CoV-2 Therapeutics	2021[b]	$447,930	University of Pennsylvania

NIH funded Remdesivir research at UNC at Chapel Hill 2017 – 2021

"**Aim 1**, we refine the pharmacokinetics, pharmacodynamics and breadth of GS-5734 through efficacy and metabolism studies in various primary human cells with a diverse array of *human and zoonotic CoV* and through the evaluation of *in vivo* efficacy in murine and non-human primate models of MERS-*and SARS-CoV*."

Broad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoV - Ralph Baric (grantome.com)

NIH-WHO Ebola Virus Clinical Trial in DR Congo: Four Experimental Therapies

Remdesivir Mortality Rates:

- Remdesivir Treatment Group, 53% (93/175)
- Remdesivir patients with more ebola virus in their blood at enrollment, 86% (highest mortality rate)
- Remdesivir use was terminated because of lethality

Ebola treatment centers in DRC used in the PALM study of Ebola therapeutics, November 20, 2018 – August 9, 2019

- INVESTIGATIONAL DRUGS REDUCE RISK OF DEATH FROM EBOLA VIRUS DISEASE, WEDNESDAY, NOVEMBER 27, 2019., WWW.NIH.GOV/NEWS-EVENTS/NEWS-RELEASES/INVESTIGATIONAL-DRUGS-REDUCE-RISK-DEATH-EBOLA-VIRUS-DISEASE;

Dr. Baric: Remdesivir Human Clinical Trial in DR Congo

"This is a game changer for the treatment of patients with COVID-19," Baric said upon hearing the results of the clinical trial. "Remdesivir provides an effective treatment strategy for the many infected individuals around the globe." April 29, 2020

- Remdesivir was developed through an academic-corporate partnership between Gilead Sciences and the Baric Lab at the University of North Carolina at Chapel Hill's *Gillings School of Global Public Health*.
- Remdesivir was deployed by the WHO and Gilead, MappBio, Regeneron, and Ridgeback Biotherapeutics

- https://sph.unc.edu/sph-news/remdesivir-developed-at-unc-chapel-hill-proves-effective-against-covid-19-in-niaid-human-clinical-trials/

Dr. Fauci: Remdesivir Human Clinical Trial in DR Congo

"Whenever you have clear-cut evidence that a drug works, you have an ethical obligation to immediately let the people who are in the placebo group know so that they can have access."

April 29, 2020

Funded & Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health

- https://sph.unc.edu/sph-news/remdesivir-developed-at-unc-chapel-hill-proves-effective-against-covid-19-in-niaid-human-clinical-trials/

CICP Data – August 1, 2022

hrsa.gov/cicp/cicp-data

New Tab Search New Tab History

HRSA
Health Resources & Services Administration

Home Grants Loans & Scholarships Data Warehouse Training & TA Hub About HRSA

Home » Countermeasures Injury Compensation Program (CICP) » Countermeasures Injury Compensation Program (CICP) Data

Countermeasures Injury Compensation Program (CICP) Data

Aggregate Data as of August 1, 2022

The Countermeasures Injury Compensation Program (CICP) provides compensation for covered serious injuries or deaths that, based on compelling, reliable, valid, medical and scientific evidence, are found to be directly caused by the administration or use of a covered countermeasure or are determined to meet the requirements of a countermeasure injury table. Temporal association between administration or use of the covered countermeasure and onset of the injury (i.e., the injury occurs a certain time after the administration or use) is not sufficient, by itself, to prove that an injury is the direct result of a covered countermeasure.

CICP Data for Fiscal Years 2010 – 2022 (As of August 1, 2022)

Total CICP Claims Filed: **9,657**

- Claims Eligible for Medical Review: **9,557**
  - Eligible for Compensation: **41**
    - Compensated: **29**
    - No Eligible Reported Expenses: **10**
    - Pending: **2**
  - Pending Review or In Review: **9,121**
  - Denied: **395**
    - Requested Medical Records Not Submitted: **135**
    - Standard of Proof Not Met and/or Covered Injury Not Sustained: **260**
- Claims Ineligible for Medical Review: **100**
  - Missed Filing Deadline: **40**
  - Not CICP Covered Product/Not Specified: **60**

- See https://www.hrsa.gov/cicp/cicp-data

COVID-19 CICP Numbers

Ventilator / Azithromycin / Convalescent Plasma / Remdesivir	Death	3
Ventilator / Azithromycin / Convalescent Plasma / Remdesivir / Solu-Medrol	Death	1
Ventilator / Azithromycin / Convalescent Plasma / Remdesivir / Steroids	Death	1
Ventilator / Azithromycin / Convalescent Plasma / Steroids	Death	1
Ventilator / Azithromycin / CRRT / Dexamethasone / Remdesivir	Death	2
Ventilator / Azithromycin / CRRT / Dexamethasone / Remdesivir / Tocilizumab	Death	1
Ventilator / Azithromycin / Decadron	Death	2
Ventilator / Azithromycin / Decadron / Methylprednisolone / Remdesivir	Death	1
Ventilator / Azithromycin / Decadron / Remdesivir	Death	2
Ventilator / Azithromycin / Decadron / Remdesivir / Solu-Medrol	Death	1

- See https://www.hrsa.gov/cicp/cicp-data

294 claims for COVID-19 injuries or deaths

98 out of 100 CICP cases where *Remdesivir* was used as a Countermeasure resulted in *death*.

Peter Daszak, President of EcoHealth Alliance

Peter Daszak and Anthony Fauci

Daszak reiterated that, until an infectious disease crisis is very real, present, and at an emergency threshold, it is often largely ignored. *To sustain the funding base beyond the crisis, he said, we need to increase public understanding of the need for MCMs (medical countermeasures) such as a pan-influenza or pan-coronavirus vaccine. A key driver is the media, and the economics follow the hype. We need to use that hype to our advantage to get to the real issues. Investors will respond if they see profit at the end of process,' Daszak stated."* (Emphasis added.)

- Developing MCMs for Coronaviruses - Rapid Medical Countermeasure Response to Infectious Diseases - NCBI Bookshelf (nih.gov).

- Name: Rodney Brooks
- Age: 58 years
- Date: October 21, 2021

I , Ms. Brooks give you 100% permission to use "our story" as it relates to the wrongful death of my husband Rodney G Brooks who was systematically murdered .

This includes anything deemed necessary for the story such as pictures, videos, and so forth.

Three Doses of Remdesivir

Tortured in ICU – 5,500+ pages of medical records

“Allergies: Covid-19 vaccines”

Died: July 21, 2022



Prosecutenow.io

- Names of sheriffs
- Names of victims
- Donate